Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Vancomycin-resistant Enterococcus" patented technology

Vancomycin-resistant Enterococcus, or vancomycin-resistant enterococci (VRE), are bacterial strains of the genus Enterococcus that are resistant to the antibiotic vancomycin.

Application of indol-ethylene substituted quinoline derivative in preparing drug-resistance bacterium medicines

The invention belongs to the technical field of medicines and in particular relates to application of an indol-ethylene substituted quinoline derivative in preparing drug-resistance bacterium medicines. The invention provides application of the indol-ethylene substituted quinoline derivative of formula (I) as shown in the specification in preparing drug-resistance bacterium medicines. The indol-ethylene substituted quinoline derivative provided by the invention has a remarkable inhibition function upon multiple drug-resistance bacteria, and is capable of remarkably inhibiting growth and propagation of vancomycin-resistant enterococcus, drug-resistant escherichia coli and methicillin-resistant staphylococcus aureus. Deep structure and function study shows that the indol-ethylene substitutedquinoline derivative provided by the invention has an action target of a bacterium split protein FtsZ, because of differences of FtsZ and human micro-tube protein sequences, drug-resistance bacteriummedicines which can selectively act upon bacteria FtsZ without interfering host cells can be designed, and the derivative is good in antibacterial activity, is capable of reducing amounts of single medicines, then reducing toxic and side effects and reducing drug resistance, and has the prospect of being developed into novel antibiotic medicines.
Owner:GUANGDONG UNIV OF TECH

(+/-)-marinopyrrole A for resisting methicillin-resistant staphylococcus aureus (MRSA) and synthesized derivative thereof

The invention relates to an inhibition activity of a synthesized derivative of a natural product (+ / -)-marinopyrrole A, shown as the chemical structural formula 1, on gram-positive bacteria, such as methicillin sensitive staphylococcus aureus (MSSA), methicillin-resistant staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), oxazocilline-resistant staphylococcus aureus (ORSA), methicillin-resistant staphylococcus epidermidis (MRSE) and the like. Furthermore, the invention also relates to a method for preparing the (+ / -)-marinopyrrole A and the derivative thereof. The method for preparing the (+ / -)-marinopyrrole A has the advantages of short synthesis route and economy and high effectiveness. According to the study of antibacterial action in vitro, the newly synthesized derivatives of the (+ / -)-marinopyrrole A have the advantages of excellent antibiotic activity on the gram-positive bacteria, such as methicillin sensitive staphylococcus aureus (MSSA), methicillin-resistant staphylococcus aureus (MRSA), vancomycin-resistant enterococcus (VRE), oxazocilline-resistant staphylococcus aureus (ORSA), methicillin-resistant staphylococcus epidermidis (MRSE) and the like, and potential clinical application prospect.
Owner:SICHUAN UNIV +1

Preparation method and application of VRE/MRSA/KPC/NDM-1 detection gene chip

The invention relates to a preparation method and application of a VRE / MRSA / KPC / NDM-1 detection gene chip. The preparation method includes: preparing specific primers, preparing specific probes, preparing an oligonucleotide chip, and building a multiple PCR system and a hybrid system. By the prepared gene chip, 5 drug-resistant genes and 3 related pathogenic bacteria can be detected at the same time, and the 5 drug-resistant genes and 3 related pathogenic bacteria include Vancomycin-resistant Enterococcus VRE drug-resistant genes VanA and VanB, an encoding New Delhi metallo-beta-lactamase-1 NDM-1 drug-resistant gene, a methicillin-resistant staphylococcus aureus MRSA drug-resistant gene mecA, an encoding carbapenemase KPC gene, an enterococcus faecalis specific gene Fddl, an enterococcus faecium specific gene Sddl and a staphylococcus aureus specific gene nuc. The chip which provides a new detection manner for the confirmation of the drug-resistant genes of common antibiotics resistance phenotypes has advantages of quickness, accuracy, high flux and the like.
Owner:INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA +1

Derivatives of marine fungal secondary metabolites and their application as anti-mrsa drugs

The invention specifically relates to gorgonian-originated fungus secondary metabolite derivatives and application of the same as antiseptics, belonging to the field of medicine. The derivatives provided by the invention exert strong inhibitory effect on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) and certain inhibitory effect on Gram-negative bacteria; and the minimal inhibition concentrations MIC of the derivatives are all less than 12.5 mu M, which proves that the derivatives can be developed into potential antibacterial drugs.
Owner:YANGZHOU UNIV

Vancomycin-resistant enterococcus multiplex fluorescence quantitative PCR (polymerase chain reaction) detection kit and detection method thereof

The invention relates to a vancomycin-resistant enterococcus multiplex fluorescence quantitative PCR (polymerase chain reaction) detection kit. The kit comprises a VanA specific primer, a VanB specific primer, a VanA fluorescent probe, a VanB fluorescent probe, a PCR buffer solution, a deoxynucleoside triphosphate mixture, a DNA (deoxyribonucleic acid) polymerase, a VanA gene standard product sequence and a VanB gene standard product sequence. The kit disclosed by the invention has the beneficial effects that due to the adoption of the PCR detection method, accurate, fast and quantitative detection can be realized.
Owner:BEIJING T&OINTL TECH

Primer, probe, method and kit for detecting VRE (Vancomycin-resistant Enterococcus spp.) gene

The invention relates to the technical field of molecular biology, and discloses a primer, a probe, a method and a kit for detecting a VRE (Vancomycin-resistant Enterococcus spp.) gene. Primers and fluorescent labeled probes are respectively designed aiming at a nucleic acid conservative region of 16S rDNA (ribosome Deoxyribose Nucleic Acid), vanA and vanB by adopting a Taqman probe real-time fluorescence PCR (Polymerase Chain Reaction) method; the 5' ends of 3 gene probes are all labeled by a fluorescent report group FAM, and 3' ends are all labeled by a fluorescent quenching group TAMRA. After the primer and the probe are prepared into a PCR detection mixed solution, enzyme and sample nucleic acid are added, an FAM channel on a fluorescent PCR instrument is selected for amplification, and detection on a target gene is realized through change of a fluorescent signal. The kit disclosed by the invention has the characteristics of high accuracy, strong specificity ad high sensitivity, and enterococcus and VRE in a urine sample can be rapidly and accurately detected.
Owner:宁波基内生物技术有限公司 +1

Quatemary ammonium chalcone derivatives resistant to drug-resistance bacteria activities, preparation method and application of quatemary ammonium chalcone derivatives

The invention belongs to the technical field of medicinal chemistry, and discloses quatemary ammonium chalcone derivatives resistant to drug-resistance bacteria activities, a preparation method and application of the quatemary ammonium chalcone derivatives. A structural formula is as shown in the description. Proved by invitro antibacterial activity experiments and erythrocyte hemolytic experiments, a large part of compounds in the series of the derivatives have great antibacterial effects and selections on staphylococcus aureus and colonic enterococcus faecalis of gram-positive bacteria, escherichia coli and pseudomonas aeruginosa of gram-negative bacteria. The selected part of compounds show great antimicrobial activities on a plurality of 'superbacteria' including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), carbapenem-resistant enterobacteriaceae (CRE) and new delhi metallo (NDM) carrying NDM genes, and especially show excellent activities on the MRSA. Proved by invitro erythrocyte toxicity experiments, the series of compounds are low in erythrocyte toxicity and can be adopted as new anti-microbial drug candidates.
Owner:ZHENGZHOU UNIV

Dialkyl cationic amphiphilic antibacterial peptide analogue with antibacterial activity and preparation method thereof

The invention belongs to the field of medicinal chemistry, and discloses a dialkyl cationic amphiphilic antibacterial peptide analogue with antibacterial activity and a synthesis method thereof. Through four-step reaction, a target product can be simply and fast obtained. A major structure is shown as the accompanying drawing. In-vitro antibacterial activity experiments prove that the most compounds in the series show good antibacterial effects on staphylococcus aureus and escherichia coli; partial compounds show excellent antibacterial activity on super bacteria including MRSA (methicillin-resistance staphylococcus aureus), VRE (vancomycin-resistant enterococcus) and CRE (carbapenemase enterobacteriaceae). In-vitro red cell toxicity experiments also show the series of compounds have low red cell toxicity, so that the series of compounds are hopeful to be used as novel antibacterial candidate medicine. The formulas are shown in the description.
Owner:ZHENGZHOU UNIV

Orixine derivative and application of orixine derivative in preparation of medicine for resisting drug-fast bacteria

The invention discloses an orixine derivative and an application of orixine derivative in preparation of medicine for resisting drug-fast bacteria, the test shows that the orixine derivative is capable of inhibiting breeding of a plurality of drug-fast bacterium in vitro, and can be used for preparing antibiotic medicines for resisting drug-fast bacteria; the orixine derivative is used for preparing medicines for resisting methicillin-resistant staphylococcus aureus (MRSA), preparing medicines for resisting benzylpenicillin-resistant staphylococcus aureus, and preparing medicines for resisting vancomycin-resistant enterococcus; the medicines can be prepared to the injection, tablet, pill, capsule, a suspending agent or an emulsion for usage, a chemical structural formula of the orixine derivative is shown in formula I, wherein R1,R2 and R3 are defined in a specification.
Owner:GUANGDONG UNIV OF TECH

Gorgonian-originated fungus secondary metabolite derivatives and application of same as antiseptics

The invention specifically relates to gorgonian-originated fungus secondary metabolite derivatives and application of the same as antiseptics, belonging to the field of medicine. The derivatives provided by the invention exert strong inhibitory effect on methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) and certain inhibitory effect on Gram-negative bacteria; and the minimal inhibition concentrations MIC of the derivatives are all less than 12.5 mu M, which proves that the derivatives can be developed into potential antibacterial drugs.
Owner:YANGZHOU UNIV

Application of adopting Mojave Bacillus KJS-3 as feed additive

The invention discloses application of adopting Mojave Bacillus KJS-3 as a feed additive. The preservation number of the Mojave Bacillus KJS-3 is KCCM10961P; the endospore conversion rate is higher than 99%; industrialized production can be realized; the strain (namely the Mojave Bacillus KJS-3) provided by the invention has broad-spectrum anti-microbial characteristic on various pathogenic fungi and pathogenic bacteria particularly harmful microorganism such as vancomycin-resistant enterococcus and resistant staphylococcus aureus; the strain can generate various digestive enzyme, vitamin, lactic acid, and other substances, is probiotics which are safe and nontoxic for animals, can be used as the feed additive, and is proved to be capable of promoting animal growth.
Owner:武汉虹睿生物科技开发有限公司

Application of benzothiazole substituted benzofuran quinoline derivative in preparation of medicament for resisting drug-resistance bacteria

The invention belongs to the technical field of drugs and particularly relates to application of benzothiazole substituted benzofuran quinoline derivative in the preparation of a medicament for resisting drug-resistance bacteria. The benzothiazole substituted benzofuran quinoline derivative provided by the invention is represented by a formula (I) (shown in the description). An action target of the benzothiazole substituted benzofuran quinoline derivative is a bacteria split protein FtsZ, and the benzothiazole substituted benzofuran quinoline derivative has an obvious inhibition effect to multiple drug-resistance bacteria, is capable of obviously inhibiting the growth and propagation of vancomycin-resistant enterococcus, methicillin-resistant staphylococcus aureus and ampicillin-resistant staphylococcus aureus, has no possibility of interfering the growth of normal cells of a host and is low in toxic and side effects and hopeful of being developed into a novel antibiotic drug; a preparation method of the benzothiazole substituted benzofuran quinoline derivative is simple, wide in raw material source and low in cost and has wide market prospects.
Owner:GUANGDONG UNIV OF TECH

Application of styrene quinoline derivative to preparation of drug-resistance bacteria antagonizing medicine and drug-resistance bacteria antagonizing medicine

The invention belongs to the technical field of medicines, particularly relates to an application of a styrene quinoline derivative to preparation of a drug-resistance bacteria antagonizing medicine and the drug-resistance bacteria antagonizing medicine, and provides the application of the styrene quinoline derivative with a structure as shown in a formula (I) to preparation of the drug-resistancebacteria antagonizing medicine. The styrene quinoline derivative has obvious inhibitory effects on positive bacteria such as vancomycin-resistant enterococcus and methicillin-resistant staphylococcusaureus, and has a certain interaction effect on negative bacteria. According to experiments of bacterial morphology under the action of the styrene quinoline derivative, people can preliminarily judge that an effect target of the styrene quinoline derivative is a ubiquitous division protein FtsZ in bacteria.
Owner:GUANGDONG UNIV OF TECH

Antibacterial macrolactin a that bacillus polyfermenticus kjs-2 produced in

The present invention relates to uses of Macrolactin A produced by Bacillus polyfermenticus KJS-2 (KCCM 10769P), which is a new bacillus strain, as an antibiotic. Macrolactin A of the present invention, which is produced by Bacillus polyfermenticus KJS-2, shows a broad spectrum of antibiotic activity against a variety of microorganisms and fungi, and is proved to be very efficient for the inhibition of particularly vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA) that are multidrug-resistant bacteria. The antibiotic Macrolactin A produced by Bacillus polyfermenticus KJS-2, can be used as an excellent antibiotic against vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus Aureus (MRSA), and thus the present invention is a very useful invention for medical industry.
Owner:INJE UNIV IND ACADEMIC COOP FOUND +1

1-substituted benzoyl-4-fatty acyl semicarbazide derivative, preparation method and application thereof as antibacterial agent

ActiveCN108456157AEnhanced inhibitory effectAntibacterial agentsOrganic active ingredientsOrtho positionMethicillin-resistant Staphylococcus epidermidis
The invention belongs to the technical field of antibacterial agents, and relates to a 1-substituted benzoyl-4-fatty acyl semicarbazide derivative, a preparation method and application thereof as an antibacterial agent. The compound is shown in a formula (I), wherein R1 is selected from hydrogen, hydroxyl, C1-C3 alkyls, C1-C8 alkoxyls, C3-C6 cycloalkyl oxyls, non-substitute or halogenated phenylsC1-C3 alkoxyls, phenyls, C1-C3 alkylbenzene, halogeno benzene, and the substitution site of R1 is selected from ortho-position or meta-position or para-position; R2 is selected from non-substitute orhalogenated C1-C8 alkyls, non-substitute or halogenated C3-C6 naphthenic bases and non-substitute or halogenated phenyl C1-C3 alkyls; X is selected from sulfur or oxygen. The 1-substituted benzoyl-4-fatty acyl semicarbazide derivative has the high inhibiting effect on drug-resistance bacteria including gram-positive bacteria, in particular to methicillin-resistant staphylococcus aureus (MRSA), methicillin-resistant staphylococcus epidermidis (MRSE) and vancomycin resistant enterococcus (VRE), and can be used for preparing novel drug resistance bacterium drugs. The formula is shown in the description.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI

Gene for mediating drug resistance of vancomycin and application thereof

The invention belongs to the technical field of biomedicine, and relates to a gene for mediating drug resistance of vancomycin and application thereof. The drug-resistant gene has a nucleotide sequence of SET ID.1, and protein encoded by the gene has an amino acid sequence of SEQ ID.2. The obtained gene sequence is a novel drug-resistance deciding gene of vancomycin resistant Enterococcus, and can prepare probe sequences of PCR amplification and gene microarray diagnostic probes for clinical diagnosis of resisting infection of the vncomycin resistant Enterococcus. The invention provides a novel detection target of drug-resistant strains for clinical practice, and provides a method for detecting Enterococcus carrying novel vancomycin resistance gene by Real-time PCR and a method for detecting the Enterococcus carrying the novel vancomycin resistance gene by a gene microarray; and the detection methods have the advantages of quickness, accuracy, simple and convenient operation, and the like.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV

Anti-methicillin-resistant staphylococcus aureus agent and Anti-vancomycin-resistant enterococcus agent

An anti-methicillin-resistant Staphylococcus aureus agent (anti-MRSA agent) and an anti-vancomycin-resistant Enterococcus agent (anti-VRE agent) contain as an active ingredient an Oobagi extract extracted from Oobagi with an extraction solvent including at least an organic solvent. Alternatively, the anti-MRSA agent and the anti-VRE agent contain as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C.
Owner:POKKA SAPPORO FOOD & BEVERAGE

Drug-resistant microbe and variant microbe disinfectant containing chlorous acid aqueous solution

InactiveCN105263327AEfficient Disinfection AbilityBiocideCosmetic preparationsEscherichia coliSalmonella enterica
The present invention provides microbe disinfectants, providing: Drug-resistant microbe disinfectants comprising a chlorous acid aqueous solution for inactivating microbes selected from methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus; and microbe disinfectants, which are made with acidity when applied to gram-negative microbes and with alkalinity when applied to gram-positive microbes. The microbes comprise at least one species of microbes selected from the group consisting of E. coli, Staphylococcus aureus, microbes of genus Bacillus, microbes of genus Paenibacillus, Pseudomonas aeruginosa, Enterococcus, Salmonella enterica, and periodontal disease microbes. The present invention is usable as a microbe disinfectant that is safe to human body and easy to handle as a microbe disinfectant for pretreatment in food processing and produces chlorous acid that generates little chlorine dioxide. The microbe disinfectant comprising a chlorous acid aqueous solution of the present invention can be utilized as a sterilizing agent, food additive, antiseptic, quasi-drug, medicine, etc.
Owner:HONBU SANKEI

Pharmaceutical composition, and preparation method and application thereof

The invention discloses a pharmaceutical composition and application thereof. The pharmaceutical composition contains compounds disclosed as chemical formula (I) or pharmaceutically acceptable salts and a pharmaceutically acceptable carrier. The pharmaceutical composition disclosed by the invention can be used for preparing antibacterial drugs, and especially preparing drugs for preventing or treating vancomycin-resistant bacterial infection diseases. The experimental data indicates that the compounds can effectively inhibit growth of vancomycin-resistant enterococcus when being combined with glycopeptide antibacterial drugs.
Owner:XIANGTAN ZHILIAN TECH MATASTASIS PROMOTE CO LTD

A multiplex fluorescent quantitative PCR detection kit for vancomycin-resistant enterococci and its detection method

The invention relates to a vancomycin-resistant enterococcus multiplex fluorescence quantitative PCR (polymerase chain reaction) detection kit. The kit comprises a VanA specific primer, a VanB specific primer, a VanA fluorescent probe, a VanB fluorescent probe, a PCR buffer solution, a deoxynucleoside triphosphate mixture, a DNA (deoxyribonucleic acid) polymerase, a VanA gene standard product sequence and a VanB gene standard product sequence. The kit disclosed by the invention has the beneficial effects that due to the adoption of the PCR detection method, accurate, fast and quantitative detection can be realized.
Owner:BEIJING T&OINTL TECH

Novel antibacterial lipopeptide compound and preparation method and application thereof

The invention discloses a novel antibacterial lipopeptide compound and a medicinal salt thereof. The structural general formula is as shown in the specification. The efficacy of the novel antibacterial lipopeptide compound is obviously superior to efficacy of daptomycin, and the anti-methicillin-resistant staphylococcus aureus (MRSA) activity of the compounds RP005 and RP012 is about ten times greater than anti-methicillin-resistant staphylococcus aureus (MRSA) activity of daptomycin. The RP005 and RP012 also simultaneously show the anti-vancomycin resistant enterococcus (VRE) activity ten times greater than anti-vancomycin resistant enterococcus (VRE) activity of daptomycin. The novel antibacterial lipopeptide compound can be used for treating infection caused by gram-positive bacteria.
Owner:美国蓝博药业公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products